What is NEUP's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for NEUP.

Stock Ratings / Health Care / NEUP / options

MRKR (35) AEON (46) RADX (46) PBM (46) ⌘ Pro Terminal →

Neuphoria Therapeutics Inc. (NEUP) Options Positioning, Max Pain & Unusual Sweeps

Q: Where is NEUP trading relative to its 50-day, 200-day, and 52-week technical levels?

NEUP last traded at $3.04 (-0.33% on volume of 52,454 shares), positioning the stock -14.12% below its 50-day simple moving average ($3.54) and -26.75% below its 200-day simple moving average ($4.15). Across its 52-week range of $3.03 to $5.53, NEUP sits at the 0.4% percentile with a 14-day RSI of 26.1 (OVERSOLD (<32)) and an implied next-earnings move of ±8.3% ($2.79 to $3.29).

$3.04 -0.33% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.03

Neuphoria Therapeutics Inc. (NEUP) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $16.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NEUP Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NEUP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Neuphoria Therapeutics Inc. (NASDAQ: NEUP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $3.04 (-0.33% 1D, market cap $16.5M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, NEUP ranks #773 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NEUP compare to MRKR and AEON in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NEUP carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -11.8%. By comparison, MRKR (Marker Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $16.3M) and AEON (AEON Biopharma Inc. (Class A)) posts a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $16.2M). Among the 5-stock peer group, NEUP leads on earnings multiple (N/A) while NEUP leads on capital efficiency (-11.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NEUP?

▼

Per NEUP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001191070), Neuphoria Therapeutics Inc. generated $15.6M in revenue (-68.8% YoY), -$369.6K in net income, and $77.2K in free cash flow against $36.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.03 (-0.25%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0.5% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 Quant Analysts Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NEUP)Realized 20D OHLCV Swing Band: ±8.3%

Deterministic 5-Pillar Attribution (31/100 Composite)

🔍 WHY NEUP SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+8/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 0.5% FCF Margin ($77.2K FCF) & 52% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (26% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$3.39+0% Next Q

Q2 (-2Q)

Grade E$3.39+0% Next Q

Q3 (-1Q)

Grade E$3.39-10.3% Next Q

Current

Grade E$3.04-9.4% Hist 90D α

Trajectory: E (39) → E (31)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NEUP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NEUP currently carries a cautious 31/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.54) and Max Pain ($3.19) forces dealer call-delta covering toward $5.81.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NEUP• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NEUP Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”

YES 31%NO 69%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±8.3%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (NEUP)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for NEUP.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NEUP)

✓Walkthrough of NEUP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NEUP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -42.53%🛡️ HOLDING TREND SUPPORT

2026-11-03O $3.06H $3.06L $3.04C $3.04VOL 70.3K

RES: $3.48SUP: $2.98SMA50: $3.54SMA200: $4.15

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NEUP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NEUP Butterfly Map → + Track NEUP →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. -68.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NEUP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NEUP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NEUP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NEUP)

Health Care Rank #773 of 1015 ⚔️ MRKR vs NEUP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NEUP vs. MRKR, AEON, RADX, PBM)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Neuphoria Therapeutics Inc. (NEUP) ranks #773 by composite RQD confidence (31/100, grade E) and #842 by equity capitalization ($16.5M). Within this direct 5-issuer industry benchmark cohort, NEUP leads on earnings valuation at N/A trailing P/E, while NEUP leads on capital efficiency and profitability with -11.8% ROIC and — gross margin. AEON currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with NEUP at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NEUP ACTIVE Neuphoria Therapeutics Inc.	E	31/100	—	—	-11.8%	-0.33%	$16.5M	Benchmark Subject
MRKR Marker Therapeutics Inc.	D-	35/100	—	—	-35.0%	-8.05%	$16.3M	/mrkr-vs-neup →
AEON AEON Biopharma Inc. (Class A)	D	46/100	—	—	-35.0%	-0.36%	$16.2M	/aeon-vs-neup →
RADX Radiopharm Theranostics Limited	D	46/100	—	—	—	-8.05%	$15.6M	/radx-vs-neup →
PBM Psyence Biomedical Ltd.	D	46/100	—	—	—	-3.93%	$17.6M	/pbm-vs-neup →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001191070 ↗

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Neuphoria Therapeutics Inc. (NEUP) reported GAAP revenue of $15.6M (-68.8% vs. FY2024 revenue of $50.1M , and -74.6% cumulative change since FY2023) , GAAP net income of -$369.6K, operating cash flow of $77.2K, and free cash flow of $77.2K (+100.5% YoY). On the balance sheet, NEUP closed FY2025 with $36.6M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$15.6M	-$369.6K	$77.2K	$77.2K	$36.6M	—
FY2024 (FY)	2024-06-30	$50.1M	-$15.5M	-$14.7M	-$14.7M	$18.2M	—
FY2023 (FY)	2023-06-30	$61.6M	-$21.4M	-$14.6M	-$14.6M	—	—

3. NEUP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NEUP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does NEUP compare to MRKR and AEON in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for NEUP?

Where is NEUP trading relative to its 50-day, 200-day, and 52-week technical levels?

NEUP last traded at $3.04 (-0.33% on volume of 52,454 shares), positioning the stock -14.12% below its 50-day simple moving average ($3.54) and -26.75% below its 200-day simple moving average ($4.15). Across its 52-week range of $3.03 to $5.53, NEUP sits at the 0.4% percentile with a 14-day RSI of 26.1 (OVERSOLD (<32)) and an implied next-earnings move of ±8.3% ($2.79 to $3.29).

Direct Sub-Reports: NEUP RQD Cockpit NEUP 12M Forecast NEUP Earnings & Move NEUP Dividends & DRIP NEUP Insiders & 13F NEUP Whale Options NEUP Profit Sankey NEUP News & Why

ROARABLE RATING BRIEF • RQD 31/100 (E) ✓ SEC XBRL & RQD VERIFIED

NEUP — Neuphoria Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-06-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

Neuphoria Therapeutics Inc. (NEUP) earns a live Roarable RQD composite score of 31/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.04 (-0.33% 1D, market capitalization $16.5M).

Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -11.8%, gross margin of —, operating margin of -7.2%, and free cash flow yield of 0.47%.
Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (7/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 5/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Neuphoria Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, classified under Biotechnology: Pharmaceutical Preparations..0B on a rounded basis, and the market data reports $16.6M.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-06-30), Neuphoria Therapeutics Inc. (NEUP) reported $15.6M in annual revenue (up from $50.1M in FY2024, -68.8% YoY) and -$369.6K in GAAP net income. Over the multi-year SEC filing window from FY2023 ($61.6M revenue, -$21.4M net income) through FY2025, NEUP scaled operating cash flow to $77.2K and free cash flow to $77.2K, backed by $36.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 31/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 0.47% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $3.03 – $5.53 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -7.2% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream suppliers, downstream customers, and sector correlations are therefore — The only sector context provided is Health Care / Biotechnology: Pharmaceutical Preparations and a beta of 1.0. No 2nd-order bottlenecks can be identified from the source data.

Key Question #1: Can NEUP sustain or expand its -7.2% operating margin and -11.8% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $15.6M and free cash flow of $77.2K, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is NEUP's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NEUP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Neuphoria Therapeutics Inc. (NEUP) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NEUP Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Aligos Therapeutics, Inc. (ALGS) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Neuphoria Therapeutics Inc. (NEUP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 1d ago

Neuphoria Therapeutics extends expiration of rights agreement to October 2027

Investing.com report covering Neuphoria Therapeutics Inc. (NEUP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Evaxion A/S (EVAX) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Neuphoria Therapeutics Inc. (NEUP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Complete U.S. Stocks List: Prices, Performance and Key Data

TradingKey report covering Neuphoria Therapeutics Inc. (NEUP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.siam.in/ • 1d ago

Neuphoria (NEUP) Stock: Falls -0.83% — Where's the Floor? 2026-10-23 - Low Beta Factor

https://www.siam.in/ report covering Neuphoria Therapeutics Inc. (NEUP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Most Active Stocks Today: U.S. Market

TradingKey report covering Neuphoria Therapeutics Inc. (NEUP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NEUP Bull vs. Bear Conversation Board — What's Your Call at $3.04?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NEUP 🐻 33% BEARISH CONVICTION

DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $3.66 (+20.0%)

📌 Pinned Debate

FY 2025 revenue of $15.6M and positive FCF of $0.1M, with cash rising to $22.2M, mark a clear improvement from the FY 2024 net loss of

Long NEUP at $3.05 targeting $3.66. FY 2025 revenue of $15.6M and positive FCF of $0.1M, with cash rising to $22.2M, mark a clear improvement from the FY 2024 net loss of -$15.5M.. Institutional whale score is 3/20 and the risk/reward vs. the $3.03 52-week low is skewed heavily in favor of bulls.

RetailWhale_TX 🐂 BULL

Both sides have a point here — NEUP's 8/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $2.59 (-15.1%)

Spot @ $3.05

An RQD score of 31 (grade E) with an Altman Z-Score of 0.2 and ROIC of -11.8% signals forensic balance-sheet and cash-generation risk.

Sitting on the sidelines or leaning short NEUP above $3.05. An RQD score of 31 (grade E) with an Altman Z-Score of 0.2 and ROIC of -11.8% signals forensic balance-sheet and cash-generation risk.. Until Fundamental Cash Engine (8/20) and FCF yield (0.47%) inflect higher, upside is capped near $5.53.